Apologies if this has already been posted. But I took some time today to read the study cited in the updated strategy presentation, from the work at the Baker Institute regarding VO2Peak as a biomarker for cardiotoxicity in chemotherapy patients.
Link to the full-text article: https://academic.oup.com/ehjcimaging/article/22/4/451/6128915?login=false
Here is a summary of some of the key points that I thought were pertinent.· LVEF is the current standard of care for evaluating cancer-treatment induced cardiotoxicity
· Emergence of heart failure with preserved LVEF as an important sub-type in cancer survivors suggests that reliance on LVEF overlooks this substantial sub-population of cancer survivors
· LVEF cut off points that are internationally recognised show little relationship with HF risk, clinical outcomes and quality of life
· Functional capacity is another potential marker of cardiac dysfunction, and is strongly associated with incident HF and all cause mortality. VO2 Peak therefore may be a sensitive means of detecting cardiotoxicity and evaluating long-term HF risk
· VO2peaks < 18 mL/kg/min is termed functional disability and is associated with a 7 to 9 fold increased risk of HF
· The American Heart Association has endorsed the measurement of functional disability as an important clinical endpoint
Trial Participants
· Participants eligible if they had been treated with anthracyclines, BTK inhibitors (ibrutinib, acalabrutinib, zanbrutinib), stem cell therapy and androgen deprivation therapy
· 58% of patients had received anthracyclines, 19% BTK inhibitors, 26% stem cell therapy and 14% androgen deprivation therapy
Results
· Functional capacity was markedly reduced at follow-up, with a 7.6% reduction in VO2Peak (p=0.016)
· The number of patients who met criteria for functional disability almost doubled
· 43% of patients experienced a clinically significant reduction in VO2 peak, conversely only negligible changes in LVEF and GLS could be measured and these showed little changes in functional capacity
· The mean 7% reduction in 4 months of treatment approximates the decline in function that would be expected in 7 years of ageing
· These declines were most apparent in patients who received anthracycline therapy
· These findings demonstrate a specificity for Vo2Peak as a measure of cardiotoxicity
Other Key Points
· Significant but negligible reductions in LVEF and GLS were detected, although the changes were rarely sufficient to be considered clinically significant
· Under the current standard of care, most decision making is based around changes in LVEF
· Despite a significant proportion of patients experiencing meaningful functional decline, only 4% of patients overall me the LVEF criteria suggestive of cardiotoxicity
· Decline in VO2Peak was almost identical in those that did and did not have a significant reduction in LVEF suggesting that LVEF is insensitive to all but marked systolic dysfunction and also functional decline
· The same can be said for GLT
· The study concludes that LVEF and GLT may provide false reassurance of low HF and CV mortality risk by missing significant reductions in VO2Peak and functional disability
- Forums
- ASX - By Stock
- RAC
- Ann: Updated Strategy and Investor Presentation
Ann: Updated Strategy and Investor Presentation, page-247
-
- There are more pages in this discussion • 262 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.50 |
Change
-0.030(1.97%) |
Mkt cap ! $257.4M |
Open | High | Low | Value | Volume |
$1.55 | $1.55 | $1.45 | $205.2K | 137.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | $1.47 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 1.470 |
1 | 10105 | 1.455 |
2 | 35000 | 1.450 |
1 | 2000 | 1.445 |
1 | 5000 | 1.440 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 1000 | 1 |
1.495 | 9786 | 2 |
1.500 | 2430 | 2 |
1.505 | 5000 | 1 |
1.510 | 381 | 2 |
Last trade - 14.35pm 21/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online